Currently Recruiting

Other Active Trials

Past Findings

ADNI

Alzheimer's Disease Neuroimaging Initiative

Status:	Active, Not Recruiting
Eligible Population(s):	Normal Controls, Mild Cognitive Impairment, Alzheimer's Disease
GCO Number:	91-208
Principal Investigator:	Hillel Grossman, MD
Study Coordinator:	Tessa Lundquist

The ADNI study may help us learn how to stop the progression of mild cognitive impairment (MCI) and Alzheimer’s disease in future generations. Information from the study might, in the future, lead to new treatments or even a cure for Alzheimer’s disease.

The goal of this study is to determine whether imaging of the brain every six months can help predict the onset and monitor the progression of Alzheimer’s disease. The imaging methods used are Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scans. In addition to neuroimaging, the study tests blood, and, for some participants, cerebrospinal fluid (from lumbar puncture) to determine if biomarkers can predict and monitor the disease.

This study is closed to recruitment.